Emtricitabine

CLINICAL USE

Nucleoside reverse transcriptase inhibitor:Treatment of HIV-1 in combination with other antiretroviral agents

DOSE IN NORMAL RENAL FUNCTION

200 mg once daily (if weight >33 kg)Oral solution: 240 mg once daily, (6 mg/kg if weight <33 kg)

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :247.2

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :<4

%Excreted unchanged in urine &nbsp &nbsp : 86

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.1–1.7

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :10/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 200 mg every 48 hours15–30 200 mg every 72 hours<15 200 mg every 96 hours

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR<15 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR<15 mL/min

HDF/high flux &nbsp :Dialysed. Dose as in GFR<15 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=15–30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antivirals: avoid concomitant use with lamivudine

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Haemodialysis should be started at least 12 hours after the last dose of emtricitabine200 mg of the hard capsules is equivalent to 240 mg of the oral solutionDose may be reduced instead of increasing dosage intervalUp to 30% of dose is removed by a 3 hour haemodialysis session.

Tags: post-by-auto-php